Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients
Authors:
- 22 June 2015
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 35 (14) , 1750-1759
Abstract
Metastasis of tumors requires angiogenesis, which is comprised of multiple biological processes that are regulated by angiogenic factors. The fibroblast growth factor (FGF) is a potent angiogenic factor and aberrant FGF signaling is a common property of tumors. Yet, how the aberration in cancer cells contributes to angiogenesis in the tumor is not well understood. Most studies of its angiogenic signaling mechanisms have been in endothelial cells. FGF receptor substrate 2α (FRS2α) is an FGF receptor-associated protein required for activation of downstream signaling molecules that include those in the mitogen-activated protein and AKT kinase pathways. Herein, we demonstrated that overactivation and hyperactivity of FRS2α, as well as overexpression of cJUN and HIF1α, were positively correlated with vessel density and progression of human prostate cancer (PCa) toward malignancy. We also demonstrate that FGF upregulated the production of vascular endothelial growth factor A mainly by increasing expression of cJUN and HIF1α. This then promoted recruitment of endothelial cells and vessel formation for the tumor. Tumor angiogenesis in mouse PCa tissues was compromised by tissue-specific ablation of Frs2α in prostate epithelial cells. Depletion of Frs2α expression in human PCa cells and in a preclinical xenograft model, MDA PCa 118b, also significantly suppressed tumor angiogenesis accompanied with decreased tumor growth in the bone. The results underscore the angiogenic role of FRS2α-mediated signaling in tumor epithelial cells in angiogenesis. They provide a rationale for treating PCa with inhibitors of FGF signaling. They also demonstrate the potential of overexpressed FRS2α as a biomarker for PCa diagnosis, prognosis and response to therapies.Keywords
This publication has 41 references indexed in Scilit:
- Role and expression of FRS2 and FRS3 in prostate cancerBMC Cancer, 2011
- A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor CellsJournal of Visualized Experiments, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanismsJournal of Clinical Investigation, 2008
- Inducible FGFR-1 Activation Leads to Irreversible Prostate Adenocarcinoma and an Epithelial-to-Mesenchymal TransitionCancer Cell, 2007
- Enhanced Paracrine FGF10 Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial Androgen ReceptorCancer Cell, 2007
- Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategiesJournal of Theoretical Biology, 2006
- Ectopic Activity of Fibroblast Growth Factor Receptor 1 in Hepatocytes Accelerates Hepatocarcinogenesis by Driving Proliferation and Vascular Endothelial Growth Factor–Induced AngiogenesisCancer Research, 2006
- FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cellsJournal of Cellular Physiology, 1999
- Breast cancer angiogenesis — new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targetingBreast Cancer Research and Treatment, 1996